These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 7879208)

  • 1. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative pilot study (report 1). Cooperative Clinical Trials in Transplantation (CCTT) Research Group.
    Transplant Proc; 1995 Feb; 27(1):863. PubMed ID: 7879208
    [No Abstract]   [Full Text] [Related]  

  • 2. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group.
    Transplantation; 1997 May; 63(9):1243-51. PubMed ID: 9158016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a Cooperative Clinical Trials in Transplantation pilot study.
    Transplantation; 1997 Apr; 63(8):1087-95. PubMed ID: 9133469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OKT4A monoclonal antibody immunosuppression of cynomolgus renal allograft recipients.
    Cosimi AB; Delmonico FL; Wright JK; Wee SL; Preffer FI; Bedle M; Colvin RB
    Transplant Proc; 1991 Feb; 23(1 Pt 1):501-3. PubMed ID: 1990600
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunosuppression of cynomolgus renal allograft recipients with humanized OKT4A monoclonal antibodies.
    Delmonico FL; Knowles RW; Colvin RB; Cavender DE; Kawai T; Bedle M; Stroka D; Preffer FI; Haug C; Cosimi AB
    Transplant Proc; 1993 Feb; 25(1 Pt 1):784-5. PubMed ID: 8438479
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody.
    Cosimi AB; Delmonico FL; Wright JK; Wee SL; Preffer FI; Jolliffe LK; Colvin RB
    Surgery; 1990 Aug; 108(2):406-13; discussion 413-4. PubMed ID: 2382234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor pretreatment in cadaver renal transplantation.
    Zincke H; Woods JE
    Surg Gynecol Obstet; 1977 Aug; 145(2):183-8. PubMed ID: 327596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor antigen-specific immunosuppression in cadaveric and living-related donor kidney allograft recipients.
    Barber WH; Hudson SL; Deierhoi MH; Laskow DA; Gaston RS; Julian BA; Curtis JJ; Diethelm AG
    Clin Transpl; 1990; ():289-300. PubMed ID: 2103152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective induction immunosuppression for cadaver renal transplantation at the St. Francis Regional Medical Center.
    Shield CF
    Clin Transpl; 1990; ():265-74. PubMed ID: 2129408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
    Friend PJ; Waldmann H; Hale G; Cobbold S; Rebello P; Thiru S; Jamieson NV; Johnston PS; Calne RY
    Transplant Proc; 1991 Aug; 23(4):2253-4. PubMed ID: 1908152
    [No Abstract]   [Full Text] [Related]  

  • 11. Single pretransplant donor-specific transfusion in cadaver and living related donor renal transplantation.
    Alexander JW; Davies CB; First MR; Cofer BR; Munda R; Madden RL; Hariharan S; Schroeder TJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):485-7. PubMed ID: 8438389
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody.
    Chatenoud L; Ferran C; Legendre C; Kurrle R; Kreis H; Bach JF
    Transplant Proc; 1990 Aug; 22(4):1787-8. PubMed ID: 2117809
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-CD4 monoclonal antibody therapy.
    Delmonico FL; Cosimi AB
    Clin Transplant; 1996 Oct; 10(5):397-403. PubMed ID: 8930451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved renal allograft survival for AHG and DTE/AHG crossmatch-negative recipients.
    Kerman RH; Kimball PM; Van Buren CT; Lewis RM; DeVera V; Baghdahsarian V; Heydari A; Kahan BD
    Transplant Proc; 1991 Feb; 23(1 Pt 1):400-2. PubMed ID: 1990565
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-LFA-1 adhesion molecule monoclonal antibody in prophylaxis of human kidney allograft rejection.
    Le Mauff B; Hourmant M; Le Meur Y; Dantal J; Cantarovich D; Caudrelier P; Alberici G; Soulillou JP
    Transplant Proc; 1995 Feb; 27(1):865-6. PubMed ID: 7879210
    [No Abstract]   [Full Text] [Related]  

  • 16. Cadaveric renal transplantation in the cyclosporine and OKT3 eras: an update of the University of Wisconsin-Madison experience.
    D'Alessandro AM; Lorentzen DF; Pirsch JD; Knechtle SJ; Reed A; Hoffmann RM; Armbrust MJ; Sollinger HW; Kalayoglu M; Belzer FO
    Clin Transpl; 1989; ():239-51. PubMed ID: 2487569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of steroid-resistant renal allograft rejection with OKT3 and plasmapheresis.
    Haberal M; Sert S; Gülay H; Arslan G; Bilgin N
    Transplant Proc; 1990 Aug; 22(4):1761-3. PubMed ID: 2117801
    [No Abstract]   [Full Text] [Related]  

  • 18. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between prophylactic use of OKT3 and cyclosporine in cadaveric renal transplantation.
    De Pauw L; Abramowicz D; Goldman M; Vereerstraeten P; Kinnaert P; Toussaint C
    Transplant Proc; 1990 Aug; 22(4):1759-60. PubMed ID: 2117800
    [No Abstract]   [Full Text] [Related]  

  • 20. Donor bone marrow transplantation: chimerism and tolerance.
    Delis S; Ciancio G; Burke GW; Garcia-Morales R; Miller J
    Transpl Immunol; 2004; 13(2):105-15. PubMed ID: 15380541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.